ResearchPad - research:-treatment https://www.researchpad.co Default RSS Feed en-us © 2020 Newgen KnowledgeWorks <![CDATA[Hypoglycaemia is reduced with use of inhaled Technosphere<sup>®</sup> Insulin relative to insulin aspart in type 1 diabetes mellitus]]> https://www.researchpad.co/article/elastic_article_6704 Hypoglycaemia and fear of hypoglycaemia are barriers to effective insulin therapy and may prevent people with diabetes from achieving glycaemic targets.Administration of inhaled Technosphere® Insulin at mealtime provides comparable glycaemic control and lower rates of hypoglycaemia across a range of HbA1c levels compared with subcutaneous insulin aspart in people with type 1 diabetes mellitus.The ultra‐rapid time‐action profile of Technosphere Insulin offers the flexibility to dose at the beginning of or 20 min after starting a meal, and allows for the convenience of between‐meal dosing with a lower risk of hypoglycaemic events compared with subcutaneous rapid‐acting insulin analogues.

]]>
<![CDATA[Insulin degludec/liraglutide ( ID egLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin]]> https://www.researchpad.co/article/N1207079a-78ff-4c67-b4c3-204fb0c994fb

Abstract

Aims

To assess whether people with type 2 diabetes transferring from higher basal insulin doses (> 20 units) to a starting dose of 16 units of insulin degludec/liraglutide (IDegLira) benefit from IDegLira with/without transient loss of glycaemic control.

Methods

Post hoc analysis of DUAL V and VII assessed fasting self‐measured blood glucose (SMBG) over weeks 1–8, changes in HbA1c, body weight and mean insulin dose over 26 weeks, and percentage of participants achieving HbA1c < 53 mmol/mol (7.0%) by end of trial in participants with type 2 diabetes uncontrolled with basal insulin. IDegLira was compared with continued up‐titration of insulin glargine (IGlar U100) in DUAL V, or switching to basal–bolus therapy in DUAL VII (IGlar U100 and insulin aspart), across pre‐trial insulin dose groups (20–29, 30–39 and 40–50 units/day).

Results

In all subgroups, participants treated with IDegLira experienced significant improvements in HbA1c by end of trial, which were greater than with IGlar U100 up‐titration (estimated treatment difference –5.86, –6.59 and –6.91 mmol/mol for pre‐trial insulin doses of 20–29, 30–39 and 40–50 units/day, respectively) and similar to basal–bolus therapy (estimated treatment difference –0.16, –1.0 and –0.01 mmol/mol for pre‐trial insulin doses of 20–29, 30–39 and 40–50 units/day, respectively). Compared with IGlar U100 and basal–bolus therapy, IDegLira participants experienced weight loss vs. weight gain, lower rates of hypoglycaemia and a lower mean end of trial total daily insulin dose. In both trials, mean fasting SMBG decreased from weeks 1 to 8 across all subgroups, despite a temporary increase in mean fasting SMBG in the 40–50 units pre‐trial insulin dose group during week 1 [mean increase (sd) +1.1 (2.0) mmol/l for DUAL V and +1.1 (2.1) mmol/l for DUAL VII], which reverted to baseline by week 4.

Conclusions

Regardless of pre‐trial insulin dose, IDegLira resulted in improved clinical outcomes, even in participants transferring from 40–50 units of basal insulin, despite a transient (< 4 weeks), clinically non‐relevant, elevation in pre‐breakfast SMBG. (Clinical Trial Registry Number NCT01952145 and NCT02420262).

]]>